Advanced Biomaterials and Biofabrication


Engineering Biomaterials to Modulate Tumor Microenvironment and Drug Delivery 

Dr. Fei Xu completed her PhD in Chemical Engineering at McMaster University, where her research focused on hydrogel chemistry, tissue engineering, and drug delivery. During her doctoral studies, she developed an innovative technique called "reactive cell electrospinning" to fabricate nanostructured, ECM-mimetic hydrogel scaffolds for tissue engineering applications. Additionally, she created a high-throughput platform for the synthesis and characterization of hydrogels used in protein-based drug delivery.

As the recipient of the prestigious PRiME postdoctoral fellowship, Dr. Xu advanced her research at the University of Toronto, where she worked on bioprinting and microfluidics for tissue regeneration and drug discovery. She is currently a postdoctoral research fellow at the University of Texas at Austin, where her work focuses on cancer vaccine delivery for immunotherapy and the development of hydrogel electrodes for treating ventricular arrhythmias.

Starting in 2024, Dr. Xu will be actively seeking a tenure-track Assistant Professor position in Biomedical Engineering, Chemical Engineering, or a related field. Her interdisciplinary research combines materials science, biomedical engineering, and drug delivery technologies to address critical challenges in health and medicine.

Education 

Ph.D. Chemical Engineering  at McMaster University 

2018

M.S. Materials Science and Engineering   Beijing University of Chemical Technology

2012

B.S. Materials Science and Engineering   Beijing University of Chemical Technology

2009


Dr. Xu's research interests lie in developing biomaterial-based in vitro platforms and drug delivery systems to study the cellular microenvironment and improve immunotherapy, with a particular emphasis on the effects of sex and aging in precision medicine. My lab will investigate how biomaterials regulate the cellular microenvironment, particularly within cancer research, and explore their potential applications in tissue regeneration and wound healing. Key objectives will include creating high-throughput drug screening platforms to identify personalized treatment options and developing localized delivery systems to overcome current challenges in immunotherapy.